canin
parvoviru
cpv
first
identifi
pathogen
respons
seriou
gastroenter
myocard
dog
current
mainli
three
antigen
type
cpv
preval
differ
countri
caus
major
infecti
diseas
threaten
dograis
industri
cpv
small
nonenvelop
singlestrand
dna
viru
linear
singlestrand
dna
genom
kb
long
contain
two
open
read
frame
orf
one
orf
encod
two
nonstructur
protein
encod
two
structur
protein
amino
acid
residu
main
compon
cpv
capsid
possess
strong
antigen
properti
canin
transferrin
receptor
tfr
identifi
receptor
cpv
infect
mediat
interact
tfr
type
ii
membran
glycoprotein
express
cell
surfac
homodim
link
two
intermolecular
disulphid
bond
monom
compris
extracellular
domain
transmembran
domain
intracellular
domain
extracellular
domain
includ
stem
proteaselik
apic
helic
region
two
disulphid
bond
locat
stem
region
normal
physiolog
condit
tfr
involv
plasmatocel
iron
transport
ironload
transferrin
tf
specif
bind
tfr
helic
region
tfr
extracellular
domain
form
tfrtf
complex
enter
cell
endocytosi
meanwhil
cpv
also
bind
tfr
apic
region
tfr
extracellular
domain
cpv
infect
host
cell
endocytosi
therefor
cpv
ironload
transferrin
bind
tfr
howev
bind
site
differ
viral
receptor
play
import
role
viru
infect
sinc
determin
speci
specif
tissu
tropism
pathogenesi
viru
viru
infect
mediat
virusreceptor
interact
block
virusreceptor
interact
common
strategi
viral
diseas
control
therefor
mani
antivir
drug
develop
base
block
virusreceptor
interact
mani
strategi
block
virusreceptor
interact
one
extens
use
strategi
antivir
research
applic
antibodi
specif
target
surfac
protein
viral
particl
spike
protein
envelop
virus
capsid
protein
nonenvelop
virus
protein
viral
surfac
involv
viral
attach
infect
host
cell
upon
bind
viral
surfac
protein
antibodi
block
virusreceptor
interact
inhibit
viru
infect
instanc
specif
antibodi
domain
sar
spike
protein
could
block
sar
infect
howev
sinc
antibodi
use
block
viru
infect
mainli
polyclon
antibodi
antisera
like
lead
anim
infect
caus
pathogen
contamin
antisera
anoth
strategi
block
virusreceptor
interact
use
small
synthet
compound
obtain
either
highthroughput
screen
larg
antivir
compound
librari
structureguid
ration
design
base
structur
interact
viral
surfac
protein
receptor
although
small
synthet
compound
may
exhibit
potent
antivir
activ
may
also
caus
side
effect
use
recombin
viru
receptor
block
interact
viru
host
cell
anoth
strategi
block
virusreceptor
interact
instanc
deen
colleagu
investig
use
solubl
form
recombin
protein
inhibit
hiv
viru
infect
result
signific
inhibit
viru
infect
base
interact
cpv
tfr
propos
canin
extracellular
domain
tfr
also
call
solubl
tfr
stfr
might
anticpv
activ
verifi
hypothesi
use
recombin
stfr
prepar
eukaryot
express
system
codonoptim
stfr
gene
test
anticpv
stfr
cultur
cell
dog
result
show
recombin
stfr
possess
signific
anticpv
activ
strain
gener
gift
dr
weiquan
liu
china
agricultur
univers
felin
kidney
cell
use
propag
cpv
human
embryon
kidney
hek
cell
use
express
recombin
stfr
china
center
type
cultur
collect
beij
cell
cell
cultur
dmem
medium
supplement
vv
fb
uml
penicillin
streptomycin
mm
lglutamin
local
healthi
mongrel
dog
week
old
kg
unvaccin
anticpv
antibodi
neg
hemagglutin
inhibit
hi
titer
use
stfr
anticpv
assay
vivo
purchas
local
dog
breeder
dog
experi
perform
accord
guid
beij
municip
review
welfar
ethic
laboratori
anim
approv
beij
municip
administr
offic
laboratori
anim
mous
antihistag
monoclon
antibodi
goat
antimous
iggap
antibodi
santa
cruz
biotechnolog
usa
use
detect
recombin
stfr
western
blot
anticpv
polyclon
antibodi
prepar
new
zealand
white
rabbit
immun
recombin
recombin
prepar
lab
chines
hamster
ovari
cho
cell
line
stabli
express
plasmid
contain
human
signal
peptid
construct
previous
describ
nintaagaros
bead
qiagen
germani
use
stfr
purif
prestain
protein
marker
biorad
protein
assay
kit
purchas
biorad
laboratori
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
purchas
gibco
brl
life
technolog
codon
stfr
optim
use
human
prefer
codon
base
codon
usag
databas
kazusa
dna
research
institut
japan
codonoptim
stfr
gene
synthes
shanghai
sangon
biolog
engin
technolog
servic
nhei
agei
restrict
site
introduc
terminu
terminu
stfr
sequenc
respect
wildtyp
stfr
gene
amplifi
canin
liver
base
genbank
sequenc
rtpcr
use
pair
primer
nhei
cggctactgt
aaacgtgtagaac
agei
aaactcattgtcaatatcccat
wildtyp
codonoptim
stfr
gene
subclon
vector
construct
eukaryot
secretori
express
vector
respect
transfect
cell
perform
use
modifi
calcium
phosphat
transfect
method
previous
describ
stfr
purif
transient
express
stfr
cell
cultur
medium
absorb
ninta
agaros
bead
ml
ninta
slurri
ml
medium
incub
overnight
shake
immobil
histag
fuse
stfr
precipit
bead
wash
four
time
wash
buffer
mm
tri
mm
nacl
mm
imidazol
ph
bound
stfr
elut
elut
buffer
mm
tri
mm
nacl
mm
imidazol
ph
elut
stfr
dialyz
pb
ph
elimin
imidazol
protein
concentr
determin
use
bradford
method
protein
sampl
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
wv
gel
separ
protein
gel
either
stain
coomassi
brilliant
blue
electroblot
onto
nitrocellulos
membran
use
semidri
electroblot
apparatu
biorad
blot
protein
membran
detect
use
mous
antihistag
monoclon
antibodi
follow
goat
antimous
igg
conjug
alkalin
phosphatas
blot
develop
use
bcipnbt
substrat
system
biorad
slightli
modifi
enzymelink
immunosorb
assay
elisa
previous
describ
use
detect
stfr
bind
activ
protein
cpv
briefli
plate
coat
cpv
dilut
coat
buffer
sodium
carbon
buffer
ph
respect
block
wv
nonfat
milk
pbst
rabbit
polyclon
antibodi
ad
cpvcoat
well
antibodi
block
test
wash
differ
amount
stfr
pbst
ad
well
stfr
bind
cpv
protein
amount
bsa
use
neg
control
mous
antihistag
antibodi
goat
antimous
iggap
use
detect
adsorb
stfr
fuse
histag
develop
phosphat
solut
optic
densiti
od
well
measur
micropl
reader
nm
stfr
bind
activ
indic
od
valu
antivir
assay
vitro
felin
kidney
cell
cultur
dmem
complet
medium
cell
reach
confluenc
cell
trypsin
seed
plate
densiti
cellswel
time
cpv
titer
mix
tfr
protein
bsa
neg
control
incub
room
temperatur
min
mixtur
ad
cell
incub
h
cell
medium
replac
dmem
complet
medium
contain
fb
antibiot
continu
cultur
h
cell
morpholog
check
differ
time
point
cultur
period
use
light
microscopi
neg
control
cell
treat
bsa
show
obvious
patholog
chang
cell
harvest
subject
repeat
freezingthaw
three
time
cpv
titer
well
measur
assay
anticpv
activ
recombin
stfr
evalu
viral
titer
reduct
felin
cell
evalu
stfr
antivir
activ
vivo
local
mongrel
dog
week
old
kg
unimmun
anticpv
antibodi
neg
screen
elisa
recombin
divid
group
eight
dog
group
preinject
intraven
stfr
mgkg
h
viru
challeng
dog
three
group
challeng
oral
infect
dog
group
dog
treat
stfr
mgkg
dose
h
viru
challeng
dog
group
neg
control
treat
bsa
time
point
dog
group
group
continu
treat
stfr
mgkgday
dose
day
challeng
morbid
mortal
rate
infect
dog
group
calcul
antivir
activ
stfr
vivo
evalu
reduct
dog
morbid
mortal
rate
cpv
amplifi
cell
viru
titer
determin
data
analyz
spss
statist
signific
differ
check
test
canin
tfr
glycoprotein
prepar
biolog
activ
stfr
eukaryot
cell
line
cell
use
first
wildtyp
stfr
gene
encod
amino
acid
sequenc
amplifi
rtpcr
stfr
codon
optim
human
prefer
codon
wildtyp
codonoptim
stfr
gene
express
vector
construct
use
vector
figur
stfr
gene
driven
cmv
promot
fuse
human
leader
sequenc
nterminu
histag
cterminu
former
mediat
stfr
secret
later
facilit
stfr
protein
purif
prepar
recombin
stfr
stfr
vector
either
wildtyp
codonoptim
transfect
cell
calcium
phosphat
transfect
method
empti
vector
neg
control
h
posttransfect
cultur
medium
harvest
recombin
stfr
purifi
ninta
agaros
identifi
sdspage
figur
b
western
blot
figur
c
shown
figur
b
c
kda
protein
band
detect
either
sdspage
western
blot
figur
b
lane
figur
c
lane
littl
higher
calcul
stfr
molecular
weight
kda
might
caus
glycosyl
result
indic
recombin
stfr
could
express
cell
secret
cultur
medium
evalu
effect
codon
optim
stfr
express
eukaryot
cell
compar
express
level
wildtyp
codonoptim
stfr
gene
cell
seen
figur
express
level
codonoptim
stfr
gene
cell
higher
wildtyp
gene
cell
indic
codon
optim
could
significantli
increas
stfr
express
eukaryot
cell
protein
identifi
interact
canin
tfr
cpv
attach
infect
host
cell
investig
whether
recombin
canin
stfr
abil
bind
cpv
use
strain
recombin
prepar
lab
test
stfr
bind
activ
use
elisa
method
bind
kinet
figur
b
show
stfr
could
bind
cpv
dosedepend
manner
bind
process
could
block
antibodi
block
capabl
directli
proport
dosag
antibodi
figur
c
result
indic
recombin
stfr
prepar
studi
bind
cpv
identifi
whether
recombin
stfr
abil
inhibit
cpv
infect
strain
incub
stfr
bsa
neg
control
ratio
viral
particl
versu
stfr
molecul
h
host
cell
infect
stfrincub
plate
morpholog
cell
examin
differ
time
point
infect
cpv
viral
titer
calcul
figur
show
morpholog
cpvinfect
cell
h
postinfect
figur
b
show
cpv
titer
cell
treat
differ
dosag
stfr
shown
figur
cytopath
effect
cpe
cell
treat
cpvbsa
much
obviou
cell
treat
stfrcpv
h
postinfect
cpv
titer
stfrcpvinfect
cell
significantli
reduc
compar
cpvbsainfect
cell
cpvinfect
cell
figur
b
degre
viru
reduct
proport
dosag
stfr
result
indic
recombin
stfr
significantli
inhibit
cpv
infect
host
cell
vitro
evalu
stfr
anticpv
activ
vivo
dog
divid
three
group
group
treat
stfr
cpv
challeng
group
treat
stfr
cpv
challeng
group
neg
control
group
treat
bsa
cpv
challeng
ten
day
postchalleng
morbid
mortal
rate
cpvinfect
dog
three
group
calcul
figur
mortal
rate
figur
b
cpvinfect
dog
either
pretreat
stfr
cpv
posttreat
cpv
stfr
stfr
tend
lower
control
cpv
bsa
notabl
mortal
rate
cpvinfect
dog
pretreat
stfr
cpv
group
decreas
time
compar
control
group
interestingli
mortal
figur
b
rate
stfrpretreat
dog
lower
stfrposttreat
dog
suggest
stfr
show
therapeut
effect
also
prevent
effect
result
preliminarili
indic
stfr
tend
inhibit
cpv
infect
vivo
present
studi
investig
whether
recombin
stfr
abil
block
cpv
infect
result
show
stfr
could
significantli
inhibit
cpv
infect
host
cell
vitro
tend
decreas
mortal
experiment
cpvinfect
dog
vivo
suggest
stfr
potenti
protect
effect
cpv
control
provid
import
clue
develop
new
anticpv
agent
base
stfr
prepar
glycosyl
dimer
recombin
tfr
eukaryot
cell
line
use
express
stfr
posttransl
glycosyl
proper
fold
cystein
residuecontain
gyc
fragment
stem
tfr
extracellular
domain
remain
stfr
gene
construct
stfr
dimer
two
helix
domain
interact
two
intermolecular
disulphid
bound
format
data
show
stfr
prepar
studi
could
bind
cpv
high
affin
suggest
stfr
possess
biolog
activ
previous
use
e
coli
express
system
prepar
recombin
stfr
result
recombin
stfr
unabl
effect
bind
cpv
probabl
due
lack
posttransl
modif
includ
glycosyl
disulphid
format
bacteri
cytoplasm
reduc
condit
favor
disulfid
bound
format
codon
optim
common
strategi
increas
recombin
protein
express
potent
signal
peptid
sequenc
could
allow
recombin
protein
effect
express
secret
adopt
strategi
codon
optim
human
mediat
highlevel
secretori
express
obtain
studi
express
level
reach
cell
lay
foundat
largescal
prepar
recombin
stfr
applic
present
studi
analyz
stfr
antivir
activ
subtyp
without
test
subtyp
specul
affin
stfr
differ
subtyp
cpv
might
differ
sinc
classif
cpv
subtyp
base
gene
sequenc
infect
cpv
host
cell
mediat
interact
thu
stfr
anticpv
activ
may
differ
distinct
subtyp
cpv
nonetheless
would
interest
import
test
anticpv
activ
stfr
subtyp
cpv
futur
studi
lastli
interact
solubl
receptor
natur
ligand
also
consid
endeavor
develop
solubl
receptorbas
antivir
agent
recombin
receptor
bind
viru
natur
ligand
recombin
stfr
bind
cpv
also
transferrin
natur
ligand
although
two
ligand
compet
bind
natur
tfr
bind
site
extracellular
domain
tfr
differ
howev
whether
recombin
stfr
interfer
transferrintfr
complex
intern
vice
versa
remain
elucid
reduc
affin
recombin
stfr
transferrin
gene
mutagenesi
would
help
weaken
side
effect
